김정범
Kim, Jeong Beom

김정범

Department of Biomedical Engineering(바이오메디컬공학과)

  • Molecular Biomedicine Lab.
  • Website
Research Interests
Reprogramming;Direct conversion;3D bioprinting;Spinal cord injury;Neurodegenerative diseases;Molecular Biomedicine;분자생의학;줄기세포;3D 바이오 프린팅;오가노이드
Lab Description
Molecular Biomedicine Lab (MBL) is a global stem cell research group that has a network with Max Planck Institute, the world-leading research institute. MBL aims to develop novel stem cell technologies to treat incurable disease. Direct conversion is a technology that can generate target cells from skin cells by bypassing the pluripotent stage thereby solving the tumorigenic risk of pluripotent stem cells. MBL focuses on developing stem cell treatments that repair damaged tissues or damaged organs using patient-specific stem cells generated by direct conversion technology, organoid technology or stem cellbased tissues produced by 3D bio-printing technology.Our research is based on an understanding of the mechanism of iPS reprogramming, direct conversion and the generation of patientspecific stem cells for future cell therapy. The aim is to develop innovative cell therapeutic methods for clinical applications and possible solutions for degenerative and currently incurable disease. In addition, iPS cells and direct conversion can also be used for innovative techniques of drug screening and toxicity tests. Therefore, the therapeutic potential of iPS cell and direct converted cells are very promising.

Kim, SuntaePark, Myung RaeChoi, CholongKim, Jeong BeomCha, Chaenyung

Article Issue Date2021-03 View4

Park, Soo YongLee, HyunahKwon, Yang WooPark, Myung RaeKim, Jae HoKim, Jeong Beom

Article Issue Date2020-04 View1
1 2 >>